A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, Efficacy and Pharmacodynamics of KBSA301 in Severe Pneumonia (S. Aureus)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, Efficacy and Pharmacodynamics of KBSA301 in Severe Pneumonia (S. Aureus)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs AR 301 (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections; Pneumonia; Staphylococcal infections
  • Focus Adverse reactions; First in man
  • Sponsors Aridis Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2017 According to an Aridis Pharmaceuticals media release, top-line results from the study have been presented at the 2017 ASM Microbe congress.
    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 05 Jan 2017 Positive clinical results from this trial announced in an Aridis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top